157066-76-7

Basic information

• Product Name: 5-[[[3-(4,4-DIPHENYL-1-PIPERIDINYL)PROPYL]AMINO]CARBONYL]-1,4-DIHYDRO-2,6-DIMETHYL-4-(4-NITROPHENYL)-3-PYRIDINECARBOXYLIC ACID METHYL ESTER HYDROCHLORIDE
• Synonyms: 5-[[[3-(4,4-DIPHENYL-1-PIPERIDINYL)PROPYL]AMINO]CARBONYL]-1,4-DIHYDRO-2,6-DIMETHYL-4-(4-NITROPHENYL)-3-PYRIDINECARBOXYLIC ACID METHYL ESTER HYDROCHLORIDE;SNAP 5089
• CAS NO: 157066-76-7
• Molecular Formula: C36H41ClN4O5
• Molecular Weight: 608.73
• Mol File: 157066-76-7.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 780.3±60.0 °C(Predicted)
• Appearance: /
• Density: 1.198±0.06 g/cm3(Predicted)
• Storage Temp.: Store at +4°C
• PKA: 14.77±0.70(Predicted)
• CAS DataBase Reference: 5-[[[3-(4,4-DIPHENYL-1-PIPERIDINYL)PROPYL]AMINO]CARBONYL]-1,4-DIHYDRO-2,6-DIMETHYL-4-(4-NITROPHENYL)-3-PYRIDINECARBOXYLIC ACID METHYL ESTER HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-[[[3-(4,4-DIPHENYL-1-PIPERIDINYL)PROPYL]AMINO]CARBONYL]-1,4-DIHYDRO-2,6-DIMETHYL-4-(4-NITROPHENYL)-3-PYRIDINECARBOXYLIC ACID METHYL ESTER HYDROCHLORIDE(157066-76-7)
• EPA Substance Registry System: 5-[[[3-(4,4-DIPHENYL-1-PIPERIDINYL)PROPYL]AMINO]CARBONYL]-1,4-DIHYDRO-2,6-DIMETHYL-4-(4-NITROPHENYL)-3-PYRIDINECARBOXYLIC ACID METHYL ESTER HYDROCHLORIDE(157066-76-7)

Safety Data

• Hazardous Substances Data: 157066-76-7(Hazardous Substances Data)

Usage

Uses

SNAP 5089 is an a1c adrenergic receptor antagonist.

Biological Activity

Subtype-selective α 1A -adrenoceptor antagonist that displays > 600-fold selectivity over other adrenoceptors (K i values are 0.35, 220, 370, 540, 800 and 1200 nM for α 1A , α 1B , α 2C , α 1D , α 2B and α 2A subtypes respectively and 540 nM for L-type Ca 2+ channels). Inhibits noradrenalin-induced contractions in rabbit vascular and lower urinary tissues.

Upstream product

• 555-16-8 4-nitrobenzaldehdye 
• 21731-17-9 methyl 3-aminocrotonate 
• 157066-75-6 acetoacetic acid N-[3-(4,4-diphenylpiperidin-1-yl)propyl]amide 

Relevant articles and documents

Use of alpha-1C specific compounds to treat benign prostatic hyperplasia

PCT No. PCT/US93/10950 Sec. 371 Date Apr. 1, 1997 Sec. 102(e) Date Apr. 1, 1997 PCT Filed Nov. 12, 1993 PCT Pub. No. WO94/10989 PCT Pub. Date May 26, 1994A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human alpha 1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human alpha 1A adrenergic receptor, a human alpha 1B adrenergic receptor, and a human histamine H1 receptor, and, binds to a human alpha 2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such alpha 1C adrenergic receptor. Compounds meeting these criteria are provided.

Aromatic amine derivatives

This invention relates to novel aromatic amine compounds having the structure: STR1 where each W, Z1 and Z2 is independently H, C1 -C6 alkyl, C1 -C6 alkoxy, OH, F, Cl, Br, I, NO2, CN, SO2 NHR3, NR42, CONR32, COR5 ; where each R1 and R2 is independently H, C1 -C6 straight or branched chain alkyl or phenyl; where each X and Y is independently CH2, NR4, S, S=O, SO2 ; where n is 0, 1 or 2; where each p and q is independently 1 or 2; where R3 is H, C1 -C6 straight or branched chain alkyl or phenyl; where R4 is H, C1 -C6 straight or branched chain alkyl or COR3 ; and where R5 is H, C1 -C6 straight or branched chain alkyl or phenyl, C1 -C6 straight or branched chain alkoxy or OH. In addition the invention includes using such compounds for the treatment of benign prostatic hyperplasia, lowering intraocular pressure and inhibiting cholesterol synthesis.

Use of α1C specific compounds to treat benign prostatic hyperlasia

A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human α1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human α1A adrenergic receptor, a human α1B adrenergic receptor, and a human histamine H1 receptor, and, binds to a human α2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such α1C adrenergic receptor. Compounds meeting these criteria are provided.